HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) in a report released on Tuesday. The firm currently has a buy rating on the stock.
Separately, Zacks Investment Research lowered Rexahn Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 10th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of $13.75.
Get Rexahn Pharmaceuticals alerts:
Shares of Rexahn Pharmaceuticals opened at $2.38 on Tuesday, according to MarketBeat. Rexahn Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $4.37.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last announced its earnings results on Monday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.04).
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Northern Trust Corp boosted its position in Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) by 61.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,213 shares of the company’s stock after buying an additional 29,354 shares during the quarter. Northern Trust Corp owned approximately 0.24% of Rexahn Pharmaceuticals worth $117,000 at the end of the most recent quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.